Trump's Foreign Aid Retreat Guts Funding for HIV Treatments, Risking Lives Globally
'People used to sell their land to buy medicines,' she recalled. It wasn't until 2011 that she began antiviral therapy, thanks to free drugs available through the US-funded President's Emergency Plan for AIDS Relief, or Pepfar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...
Net Sales: SEK178 million in Q2, with an organic growth of -11%. Gross Margin: Stable at 74% for both Q2 and year-to-date. Adjusted EBITDA: 13% for the quarter. Thoracic Sales: SEK105 million in Q2, with an organic growth of -19%. Lung Sales: Negative growth of -10% in local currencies; however, outside the largest US customer, lung sales grew by 26%. Heart Sales: SEK3 million in Q2, compared to SEK19 million last year. Abdominal Sales: SEK52 million, with an organic growth of 19%. Liver Sales Growth: 28% in local currencies, with 32% growth in main European markets. Kidney Sales: Declined by 2%, but US Kidney Assist Transport disposables grew by 47%. Services Sales: SEK21 million, with organ recovery part decreasing by 19%. Operating Cash Flow: Positive SEK9 million in Q2. Investments: SEK72 million, primarily for US clinical trials and perfusion devices. Release Date: July 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Xvivo Perfusion AB (XVIPF) reported strong growth in specific segments, with US lung sales to clinics and OPOs growing by 26%, liver sales in Europe increasing by 32%, and kidney sales in the US rising by 47% during the second quarter. The company achieved significant milestones for future growth, including a 76% risk reduction in severe PGD from the European Heart Study, which led to improved patient survival. There is a high interest in starting EVLP programs, with four new XPS customers in the US in the first six months of 2025, indicating potential for future growth. Xvivo Perfusion AB (XVIPF) maintained a stable gross margin of 74% despite currency headwinds, demonstrating resilience in its business model. The company is preparing for the launch of heart products in Europe and has seen high interest from clinics, indicating potential for future revenue growth in this segment. Xvivo Perfusion AB (XVIPF) reported negative top-line growth in Q2 2025 compared to the same quarter last year, primarily due to a slower-than-expected lung market, lack of heart sales, and a weaker US dollar. The company's EBITDA as a percentage of sales decreased this quarter, reflecting challenges in maintaining profitability amidst sales declines. There was a significant destocking issue with the largest US lung customer, impacting sales negatively by approximately USD 1.5 million. Heart sales were significantly lower in Q2 2025 compared to last year, with only SEK3 million in sales versus SEK19 million last year, due to the absence of trial revenue. The US service business progress was unsatisfactory, with a strategic review indicating a need for improvement in this area. Q: Can you provide more details on the destocking issue with your largest lung customer and when it might end? A: The destocking was unexpected due to slower growth in the EVLP market. It will likely stop when the market returns to normal growth levels. If the market stabilizes, we don't expect further inventory reductions. The impact in Q2 was approximately USD 1.5 million. Christoffer Rosenblad, CEO Q: With new EVLP centers ramping up in the US, do you expect growth from direct US lung customers to accelerate? A: We aim to accelerate growth by investing in customer-facing personnel to ramp up new accounts. We are planning for a better second half compared to the first half. Christoffer Rosenblad, CEO Q: What is the expected sales contribution from heart products in Europe if approval is received in Q3? A: Sales will ramp up gradually as we list the product country by country and activate clinics. We expect increasing sales quarter-on-quarter rather than a high initial launch volume. Christoffer Rosenblad, CEO Q: What is the status of the liver trial and the continuous access protocol for heart in the US? A: The first patient for the heart protocol could be any day, depending on waitlist matching. For the liver trial, we aim to include the first patient by the end of Q3. Christoffer Rosenblad, CEO Q: How is the interest from OPOs affecting your strategy, and what is the timeline for supporting them? A: We see OPOs as a crucial customer group due to the NRP trend. We have some homework to do to best cooperate with them, but we expect to be ready to support them in less than 12 months. Christoffer Rosenblad, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
10 hours ago
- CNBC
Bill Gates says Trump's cuts to USAID are devastating: 'It's not too late to reverse them'
Bill Gates, the philanthropist and Microsoft co-founder, on Friday said it's not too late to reinstate international aid funding that President Donald Trump cut off. The Trump administration placed staff members at the U.S. Agency for International Development, or USAID, on administrative leave in February. The last day of the independent agency was June 30. "The devastating effects of these cuts are entirely preventable—and it's not too late to reverse them," Gates wrote in an X post on Friday. Gates referred to a post from Sam Stein, managing editor at political news site The Bulwark and an MSNBC contributor, containing comments from an unnamed aid worker in Africa. The worker said shipments of HIV medication for children had not arrived in months, and existing supplies will expire within weeks. The worker also described shortages of oxygen tubes for newborn babies and medication for sexually transmitted diseases. Last week, Secretary of State Marco Rubio said that "moving forward, our assistance will be targeted and time limited." USAID was absorbed into the State Department. The State Department is reviewing funding from the United States President's Emergency Plan for AIDS Relief, or PEPFAR, a spokesperson told NPR in June. Gates' comments come a week after he said the aid rollbacks have already led to deaths. Gates, chair of the nonprofit Gates Foundation, spoke about the cuts during an address in Ethiopia in June. "A lot of cuts are being made in foreign aid programs," he said during the visit, according to a transcript of the remarks. "Some of those cuts are being made so abruptly that there are complete interruptions in trials, or medicines are still sitting in warehouses and are not available. And these cuts are something that I think are a huge mistake." The foundation has collaborated with USAID for years, and it has spent billions on global development and global health, having made thousands of grants. When the foundation announced in May that Gates would give away almost all his money over the next two decades, it said that "governments around the world have announced tens of billions of dollars in cuts to aid funding." In addition to reducing PEPFAR and USAID commitments, Trump's administration has indicated that it will end its backing of the vaccine group Gavi, which the Gates Foundation helped to set up in 1999 and has continued to support. Last fall, Gates gave $50 million for the campaign of Democratic presidential candidate Kamala Harris. In late December, Gates had dinner with Trump at the president's Mar-a-Lago resort in Florida. Rubio has declined to meet with Gates since the former Republican presidential hopeful became secretary of state in January, The New York Times reported.
Yahoo
12 hours ago
- Yahoo
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Testing & Diagnostics Services company Guardant Health (NASDAQ:GH) fell 3.2%. Is now the time to buy Guardant Health? Access our full analysis report here, it's free. Therapeutics company Gilead Sciences (NASDAQ:GILD) fell 3.7%. Is now the time to buy Gilead Sciences? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) fell 4.7%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) fell 4.9%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Specialized Medical & Nursing Services company AMN Healthcare Services (NYSE:AMN) fell 3.2%. Is now the time to buy AMN Healthcare Services? Access our full analysis report here, it's free. Enovis's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Enovis is down 22.9% since the beginning of the year, and at $34.15 per share, it is trading 30.8% below its 52-week high of $49.33 from December 2024. Investors who bought $1,000 worth of Enovis's shares 5 years ago would now be looking at an investment worth $401.24. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
